Baumer SA develops solutions in hospitals and health industry equipments. It has various segments like Orthopedic Implants, Biomaterials, Sterilization, Infections Control, Surgical Centers, Water Treatment and solid residuals Health Treatment Divisions. The company also provides surgical center solutions, including anesthesia systems, lighting products, surgical tables, and orthopedic solutions consisting of hip and knee prosthesis, shoulder prosthesis, non-conventional orthopedic solutions, intramedullary fixation solutions, external and internal fixations, and biomaterials. In addition, it offers spine solutions, such as fixation system locks, occipitocervial fixation systems, angled cervical cages, and posterior lumbar cages.
1952
n/a
Last FY Revenue $36.5M
Last FY EBITDA $10.0M
$23.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Baumer reported revenue of $36.5M and EBITDA of $10.0M.
Baumer expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Baumer valuation multiples based on analyst estimatesNTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|
Revenue | XXX | $36.5M | XXX | XXX | XXX |
Gross Profit | XXX | $22.5M | XXX | XXX | XXX |
Gross Margin | XXX | 62% | XXX | XXX | XXX |
EBITDA | XXX | $10.0M | XXX | XXX | XXX |
EBITDA Margin | XXX | 27% | XXX | XXX | XXX |
EBIT | XXX | $6.9M | XXX | XXX | XXX |
EBIT Margin | XXX | 19% | XXX | XXX | XXX |
Net Profit | XXX | $5.5M | XXX | XXX | XXX |
Net Margin | XXX | 15% | XXX | XXX | XXX |
Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Baumer has current market cap of BRL 186M (or $35.0M), and EV of BRL 125M (or $23.5M).
As of September 23, 2025, Baumer's stock price is BRL 19 (or $4).
See Baumer trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$23.5M | $35.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialBaumer's trades at 0.6x EV/Revenue multiple, and 2.4x EV/EBITDA.
See valuation multiples for Baumer and 15K+ public compsAs of September 23, 2025, Baumer has market cap of $35.0M and EV of $23.5M.
Equity research analysts estimate Baumer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Baumer's P/E ratio is not available.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $35.0M | XXX | $35.0M | XXX | XXX | XXX |
EV (current) | $23.5M | XXX | $23.5M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | 0.6x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | 2.4x | XXX | XXX | XXX |
EV/EBIT | n/a | XXX | 3.4x | XXX | XXX | XXX |
EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | 6.4x | XXX | XXX | XXX |
EV/FCF | n/a | XXX | 4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBaumer's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Baumer's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Baumer's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Baumer and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | 27% | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Baumer acquired XXX companies to date.
Last acquisition by Baumer was XXXXXXXX, XXXXX XXXXX XXXXXX . Baumer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was Baumer founded? | Baumer was founded in 1952. |
Where is Baumer headquartered? | Baumer is headquartered in Brazil. |
Is Baumer publicy listed? | Yes, Baumer is a public company listed on BVMF. |
What is the stock symbol of Baumer? | Baumer trades under BALM4 ticker. |
When did Baumer go public? | Baumer went public in 2005. |
Who are competitors of Baumer? | Similar companies to Baumer include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
What is the current market cap of Baumer? | Baumer's current market cap is $35.0M |
Is Baumer profitable? | Yes, Baumer is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.